Agnes Lteif

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Hope S. Rugo, Fabrice André, Toshinari Yamashita et al. · Annals of Oncology · 2020 · 187 citations · Full text

Medicine, Oncology, Pharmacology +15

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Anwesha Chaudhury, Nadia Solovieff, Laia Paré et al. · Journal of Clinical Oncology · 2021 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer

Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz et al. · Therapeutic Advances in Medical Oncology · 2023 · 99 citations · Full text

Medicine, Endocrinology, Oncology +17

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

Fabrice André, Faye Su, Nadia Solovieff et al. · Annals of Oncology · 2023 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat, Nadia Solovieff, Fabrice André et al. · Clinical Cancer Research · 2023 · 22 citations · Full text

Medicine, Oncology, Pharmacology +16